LLY icon

Eli Lilly

733.29 USD
+17.73
2.48%
At close May 15, 4:00 PM EDT
After hours
732.00
-1.29
0.18%
1 day
2.48%
5 days
-2.49%
1 month
-3.16%
3 months
-14.46%
6 months
-1.73%
Year to date
-5.76%
1 year
-6.83%
5 years
360.52%
10 years
905.88%
 

About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Employees: 47,000

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

142% more first-time investments, than exits

New positions opened: 475 | Existing positions closed: 196

6% more funds holding

Funds holding: 3,608 [Q3] → 3,816 (+208) [Q4]

4% more repeat investments, than reductions

Existing positions increased: 1,506 | Existing positions reduced: 1,451

0.14% more ownership

Funds ownership: 81.8% [Q3] → 81.94% (+0.14%) [Q4]

9% less call options, than puts

Call options by funds: $9.28B | Put options by funds: $10.1B

11% less capital invested

Capital invested by funds: $676B [Q3] → $604B (-$72.2B) [Q4]

30% less funds holding in top 10

Funds holding in top 10: 463 [Q3] → 325 (-138) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$700
5%
downside
Avg. target
$966
32%
upside
High target
$1,124
53%
upside

7 analyst ratings

positive
86%
neutral
0%
negative
14%
UBS
Trung Huynh
42% 1-year accuracy
5 / 12 met price target
43%upside
$1,050
Buy
Maintained
2 May 2025
HSBC
Rajesh Kumar
67% 1-year accuracy
2 / 3 met price target
5%downside
$700
Reduce
Downgraded
28 Apr 2025
Cantor Fitzgerald
Carter Gould
26% 1-year accuracy
8 / 31 met price target
33%upside
$975
Overweight
Initiated
22 Apr 2025
Guggenheim
Seamus Fernandez
36% 1-year accuracy
8 / 22 met price target
27%upside
$928
Buy
Maintained
14 Apr 2025
Morgan Stanley
Terence Flynn
41% 1-year accuracy
9 / 22 met price target
53%upside
$1,124
Overweight
Maintained
9 Apr 2025

Financial journalist opinion

Based on 169 articles about LLY published over the past 30 days

Neutral
Seeking Alpha
6 hours ago
Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript
Eli Lilly and Company (NYSE:LLY ) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - SVP, IR Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us. I'm Tim Anderson, the U.S. Pharma and Biotech analyst at Bank of America.
Eli Lilly and Company (LLY) BofA Securities 2025 Health Care Conference Call Transcript
Negative
The Motley Fool
16 hours ago
2 Stocks That Plummeted During President Trump's First 100 Days in Office, and Where They Could Be Headed
President Donald Trump's first 100 days in office occurred between Monday, Jan. 20, and Tuesday, April 29. During this period, the S&P 500 (^GSPC 0.10%) and Nasdaq Composite (^IXIC 0.72%) dropped by 7% and 11%, respectively.
2 Stocks That Plummeted During President Trump's First 100 Days in Office, and Where They Could Be Headed
Positive
Zacks Investment Research
1 day ago
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
Positive
Zacks Investment Research
2 days ago
PFE vs. LLY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?
PFE vs. LLY: Which Stock Is the Better Value Option?
Negative
Barrons
2 days ago
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
Neutral
Zacks Investment Research
2 days ago
Why Lilly (LLY) International Revenue Trends Deserve Your Attention
Examine Lilly's (LLY) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Why Lilly (LLY) International Revenue Trends Deserve Your Attention
Positive
Zacks Investment Research
2 days ago
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared
Neutral
FXEmpire
2 days ago
NVO, PFE and LLY Forecast – Pharma Stocks React to Drug Order Trump Signs
The executive order that Donald Trump has signed over the last 24 hours could have a significant effect on pharmaceutical companies, and as a result, we should be paying attention to this sector.
NVO, PFE and LLY Forecast – Pharma Stocks React to Drug Order Trump Signs
Positive
Seeking Alpha
3 days ago
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies, including Pfizer and Nordstrom, met the "safer" qualification with free cash flow yields exceeding dividend yields. Analysts estimate net gains of 19.58% to 41.46% for top Fortune 50 WMA companies by May 2026, with Novo Nordisk leading.
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
Neutral
Reuters
3 days ago
Trump calls out weight-loss drugs as target of price-cut push
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its push to lower prescription drug prices.
Trump calls out weight-loss drugs as target of price-cut push
Charts implemented using Lightweight Charts™